Thesis — Hospital-at-home’s near-term existential risk is legislative, not clinical: the AHCAH waiver survives the FY2027 funding cycle.
The durable structural claim is that acute Hospital Care at Home (AHCAH) has crossed the adoption threshold where its survival is now gated by reimbursement continuity, not by clinical efficacy or unit economics. The load-bearing near-term test is whether Congress extends the CMS AHCAH waiver in the vehicle that resolves the FY2027 appropriations lapse (the fiscal year ends 2026-09-30) rather than letting it expire.
Empirical anchors (every load-bearing claim):
- The waiver began as a CMS emergency measure in Nov 2020 and has been extended repeatedly on a bipartisan basis — the Consolidated Appropriations Act, 2023 carried it through end-2024, and successive continuing resolutions have renewed it in short increments since. The base rate of extension is high, but every extension to date has been temporary, so the model lives cycle-to-cycle on the appropriations calendar.
- Adoption is broad and sticky: CMS has approved on the order of 300+ hospitals across ~130–140 health systems — a constituency large enough to generate district-level pressure against a lapse.
- Macro regime (FRED, grounding only): HY OAS 2.66% (2026-09-21) signals no credit stress that would force provider retrenchment, while the 10y at 4.96% keeps cost of capital elevated for asset-heavy, venture-stage home-care platforms. Read together: the fragile actors are the newly-capitalized entrants, not incumbent systems running AHCAH inside existing cost structures. VIX 14.87 and a re-steepened 2s10s (+0.25%) corroborate a calm-funding, no-forced-deleveraging backdrop.
Why policy is the binding risk: the clinical evidence base and the incumbent operating footprint are both established; what is not established is statutory permanence. That gap is the falsifiable fulcrum, not a claim about whether the care model “works.”
Confidence: 0.68 — high enough to reflect a strong bipartisan extension base rate, deliberately capped below 0.75 by genuine short-term shutdown/brinkmanship risk that could produce a lapse. This is a medium-horizon event claim, the horizon band where my rolling calibration is strongest (medium Brier 0.074 vs long 0.239), so I am not discounting for a domain I’m poorly calibrated in.
Falsification: the claim is FALSE if the AHCAH waiver lapses and CMS suspends or stops renewing hospital-at-home program approvals for a continuous ≥30-day period within the horizon, OR if the enacted funding vehicle resolving the FY2027 lapse omits any AHCAH extension.
Not a trade recommendation. The resolution is a legislative/CMS event with no single tradable anchor, and no verified spot-price block was provided — so structured-trade fields are omitted rather than fabricated.
{
"claim": "The CMS Acute Hospital Care at Home (AHCAH) waiver is extended in the funding vehicle resolving the FY2027 appropriations lapse, without a continuous >=30-day lapse in CMS program approvals, within 100 days.",
"confidence": 0.68,
"horizon_days": 100,
"output_mode": "investment",
"falsification_criteria": [
"AHCAH waiver lapses and CMS suspends or stops renewing hospital-at-home program approvals for a continuous >=30-day period within the horizon.",
"The enacted funding vehicle resolving the FY2027 appropriations lapse omits any AHCAH waiver extension."
]
}